Led by International Myeloma Society (IMS), the 17th International Myeloma Workshop (IMW) will be held in Boston, USA, from 12 to 15 September. During the Workshop the latest breakthroughs in myeloma and related diseases will be presented and analysed by leading doctors, researchers and patient advocates in the community. Continue reading
European Commission (EC) has approved elotuzumab –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. Continue reading
DREAMM-2, the pivotal open-label, randomised study of two doses of belantamab mafodotin has reported a clinically meaningful overall response rate (ORR) in relapsed myeloma patients. Continue reading
With the aim of addressing common educational needs of the cancer advocacy community, the Workgroup of European Cancer Patient Advocacy Networks (WECAN) held the first WECAN Academy from 6-9 July 2019 in Frankfurt, Germany. Continue reading
MMPredict is a HORIZON 2020 project, which Myeloma Patients Europe (MPE) is involved in, aimed at clinically validating a personalised medicines tool that predicts the most effective treatment options for myeloma patients.
As part of MMPredict, MPE has been involved in the development and dissemination of a survey assessing the quality of life of European myeloma patients, particularly relating to currently available myeloma treatments and how side-effects impact upon them. Continue reading
The pharmaceutical company Janssen, who produce a range of myeloma medicines, have today announced their application to the European Medicines Agency (EMA) for a license extension for daratumumab. This license extension, if approved by the EMA, would allow the use of subcutaneous (under the skin) daratumumab (Darzalex®) in myeloma patients. Continue reading
The first WECAN Academy organised by the Workgroup of European Cancer Patient Advocacy Networks (WECAN) will take place 6-9 July 2019 in Frankfurt, Germany. This training programme is aimed at growing the knowledge and skills of more than 100 European leading patient advocates, and those who joined the community more recently, in the areas of: Continue reading
MPE held a webinar on personalised medicines in myeloma with the aim of providing an overview of how haematologists adapt treatment to each patient and to discuss the barriers healthcare systems have to face.
The talk was given by Dr Annemiek Broijl, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
The HARMONY Alliance is a public-private partnership of more than 80 organizations (53 Partners and 35 Associated Members) funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021). Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance.
Myeloma is the disease with the highest number of approved drugs over the last 15 years. Actually, the prognosis of the disease has been tripled. As myeloma is a very heterogeneous disease, not all treatments are suitable for each patient. The challenge now is to choose the right treatment for each individual patient in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and reduce healthcare costs.
With the aim of providing an overview of personalised medicines in myeloma, Myeloma Patients Europe (MPE) will hold a webinar on Tuesday 25 June from 18:00 to 19:00 CET. Continue reading